Metsera reports promising Phase 1 trial results for obesity treatment

NEW YORK - Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company valued at $2.89 billion, today revealed positive topline results from its Phase 1 clinical trial for MET-233i, an amylin analog designed for obesity treatment. The trial found up to 8.4% mean placebo-subtracted weight loss at Day 36 and supported the potential for once-monthly dosing due to its observed 19-day half-life. According to InvestingPro data, the company maintains a strong financial health score of 2.8, with a comfortable current ratio of 6.55, indicating robust operational stability.

The randomized, placebo-controlled, double-blind study involved 80 participants with overweight or obesity but without type 2 diabetes. MET-233i was administered in single doses ranging from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration. The trial’s findings also indicated favorable tolerability with no severe or serious adverse events reported. Wall Street analysts maintain a Strong Buy consensus on MTSR, with price targets ranging from $38 to $56, reflecting confidence in the company’s clinical development program.

MET-233i’s pharmacokinetics showed dose-linear characteristics and compatibility with Metsera’s GLP-1 receptor agonist candidate, MET-097i, suggesting the potential for a first-in-category monthly multi-NuSH combination therapy. The company’s Chief Medical Officer, Dr. Steve Marso, highlighted the drug’s efficacy and tolerability, positioning MET-233i as a potential best-in-class amylin.

Metsera is advancing MET-233i as a monotherapy and in combination with MET-097i, with ongoing trials expected to yield further data by late 2025 or early 2026. In addition, Metsera anticipates reporting clinical data from its GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025.

The company’s HALO™ peptide stabilization and lipidation platform technology underpins the development of MET-233i, aiming to provide monthly dosing options and improved scalability.

This announcement was made in conjunction with a conference call and webcast hosted by Metsera to discuss the Phase 1 clinical trial findings. The information is based on a press release statement from Metsera, Inc. Investors looking for deeper insights into Metsera’s financial health and growth potential can access additional analysis through InvestingPro, which offers exclusive metrics, Fair Value assessments, and 8 more key investment tips for MTSR.

In other recent news, Metsera Inc. has been the focus of several noteworthy developments. Cantor Fitzgerald has reiterated its Overweight rating on Metsera, highlighting the company’s promising pipeline aimed at addressing the obesity market. Analysts at Cantor Fitzgerald emphasized Metsera’s scalability and low capital expenditure requirements, which they believe will aid in derisking its innovative therapies. Meanwhile, Metsera has strengthened its leadership team by appointing Jon P. Stonehouse to its Board of Directors and Matthew Lang as Chief Legal Officer and Secretary, enhancing its governance structure.

Additionally, Metsera’s Board of Directors has approved full 2024 annual cash bonuses for its executive officers, reflecting the company’s performance. Notably, CEO Christopher Whitten Bernard received a bonus of $241,644, contributing to his total compensation of $5,969,222 for the year. The bonuses align with Metsera’s compensation policy and demonstrate the company’s commitment to transparency in financial decisions. These recent developments underscore Metsera’s strategic focus and operational progress in the competitive pharmaceutical landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.